Company Analysis
Sign in

Xilio Therapeutics, Inc. (XLO)

Nasdaq: XLO · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.7
◀ Past 4.1● Present 4.1▶ Future 5.9
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$43.8M+589.9%
Net income-$35.0M+39.8%
Earnings per share$-4.19+72.5%
Operating cash flow-$5.0M+72.8%
Cash$139M+144.1%
Debtn/a
Shareholders’ equity$35.3M+100.4%
Shares, diluted8,359,109+118.7%
Return on equity-99.3%
The recordfrom its filings
Filings in 202657
Newest filingNov 12 · SCHEDULE 13G
Annual reportMar 23, 2026
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted8
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $55.0MNet income -$11.5MCash from operations -$56.9Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 2, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton XLO · research, not advice